Open AccessCase Report
Extended Survival in a Dog with Primary Bone Hemangiosarcoma Following Treatment with Neoadjuvant Oncolytic Virotherapy and Standard of Care
by
Courtney Labé, Andrea Chehadeh, Amber Winter, Sara Pracht, Kathy M. Stuebner, Mitzi Lewellen, Bishoy Eskander, M. Gerard O’Sullivan, Alexandru-Flaviu Tabaran, Christopher Ober, Michael S. Henson, Davis Seelig, Steve J. Russell, Jaime F. Modiano, Shruthi Naik and Kelly M. Makielski
Abstract
A three year old male neutered mixed breed dog presented with a mass on the right carpus and accompanying lameness. A Jamshidi bone biopsy was performed, and histopathology results were consistent with a sarcoma. The dog received oncolytic virotherapy (OV) with vesicular stomatitis
[...] Read more.
A three year old male neutered mixed breed dog presented with a mass on the right carpus and accompanying lameness. A Jamshidi bone biopsy was performed, and histopathology results were consistent with a sarcoma. The dog received oncolytic virotherapy (OV) with vesicular stomatitis virus (VSV) as part of a clinical trial in dogs with osteosarcoma (OSA). Ten days after VSV treatment, the affected limb was amputated, and histopathology was consistent with intramedullary HSA. Considering the new diagnosis, standard doxorubicin chemotherapy was prescribed. With this combination of therapies, the dog had an extended survival of more than seven years and remains alive at the time of writing. This is the first case report documenting OV given in conjunction with the standard of care for canine appendicular HSA.
Full article
►▼
Show Figures